For steady infusions octagam®5% | For fast infusions octagam®10% | |
|---|---|---|
IgG concentration³˒⁴ | 50 mg/mL | 100 mg/mL |
Shelf life³˒⁴ | 24 months | 36 months |
Maximum infusion speed³˒⁴ | 5 mL/kg/hour | 7.2 mL/kg/hour |
Storage³˒⁴ 2°C–8°C: |
| 36 months |
Storage³˒⁴ < 25°C: | 24 months | 9 months |
Vial sizes³˒⁴, mL | 50 mL, 100 mL, 200 mL, 500 mL | 20 mL, 50 mL, 100 mL, 200 mL, 300 mL |
Vial sizes³˒⁴, gram | 2.5 g, 5 g, 10 g, 25 g | 2 g, 5 g, 10 g, 20 g, 30 g |
Dosing and Infusion
Convenient dosing
Octagam® provides flexibility and choice with individualized and convenient dosing.
Octagam® is available in a wide range of vial sizes for customised dosing.3,4
Efficient handling
Available in two concentrations
No need for reconstitution
No need for an in-line filter
Choice of vial sizes to meet individual needs
Colour-coded packaging and vials
Integrated vial hanger for ease of use
Tamper-evident packaging
Storage at room temperature
Octagam® is available in two concentrations: 5% and 10%
Dosing recommendation
Dose | |
|---|---|
Primary Immunodeficiency | 0.2–0.8 g/kg every 3–4 weeks |
Secondary Immunodeficiency (incl. congenital AIDS and HSCT) | 0.2–0.4 g/kg every 3–4 weeks |
Primary immune thrombocytopenia | 0.8–1.0 g/kg on day 1 repeated within 3 days or 0.4 g/kg per day for 2–5 days |
Guillain Barré syndrome | 0.4 g/kg per day for 5 days |
Kawasaki disease | 1.6–2.0 g/kg divided over 2–5 days taken with ASA or 2.0 g/kg single dose taken with ASA |
Chronic inflammatory demyelinating polyneuropathy | 2.0 g/kg divided over ≤5 consecutive days every 4 weeks.* |
(Octagam®10% only) Dermatomyositis | 2.0 g/kg given divided in equal doses over 2-5 consecutive days every 4 weeks |
*Initial dose recommendation. The maintenance dose must be adapted to the individual clinical response.
Infusion rate recommendations3,4
Initial infusion rate | Maximum infusion rate | |
|---|---|---|
octagam®5% | 0.02 mL/kg/min | 0.08 mL/kg/min |
octagam®10%* | 0.01 mL/kg/min | 0.12 mL/kg/min |
*For Adult DM only:
Initial infusion rate : 0.01 mL/kg/min for first 30 minutes
Maximum (if tolerated): 0.04 mL/kg/min
For further recommendations for infusing DM patients, refer to specific information on dermatomyositis.
Please refer to the approved SPC or your local Product information for further information on octagam dosing and administration for all approved indications.
Octagam® IVIg tolerability considerations:
Octagam® is generally well tolerated.3,4
Common (>1%–<10%): hypersensitivity, headache, nausea, fever, fatigue, injection site reaction.
Uncommon (>0.1%–<1%): eczema, back pain, chest pain, chills.
The above list of adverse drug reactions (ADRs) are those identified in clinical trials with octagam®. For further information on ADRs and those that have been identified during post approval use of octagam®5% and octagam®10%, refer to the approved prescribing information.
Administration of octagam®
Certain severe adverse drug reactions reported with the administration of IVIg products may be related to the rate of infusion. The recommended infusion rates should be closely followed and patients closely monitored and observed for any symptoms throughout the infusion period, and in line with your local product administration policies.
References
3. octagam®5%. Summary of Product Characteristics. May 2021.
4. octagam®10%. Summary of Product Characteristics. May 2021.
This is an international website for octagam® and is intended for healthcare professionals outside the US. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.
IMPORTANT: The information on this website is based on the European Summary of Product Characteristics (EU SmPC).
If you wish to contact Octapharma please use the contact form on our corporate website.
